Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.

被引：0
作者：
Hamai, Kosuke
Masuda, Takeshi
Fujitaka, Kazunori
Suzuki, Tomoko
Matsumoto, Naoko
Matsumura, Mirai
Isoyama, Shoko
Ueno, Sayaka
Mito, Mineyo
Yamaguchi, Kakuhiro
Sakamoto, Shinjiro
Kawano, Reo
Masuda, Ken
Nishino, Ryohei
Ishikawa, Nobuhisa
Yamasaki, Masahiro
Hattori, Noboru
机构：
[1] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[2] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[3] JA Onomichi Gen Hosp, Dept Resp Internal Med, Onomichi, Japan
[4] Hiroshima Red Cross Hosp & Atom Bomb Survivors Ho, Dept Resp Internal Med, Hiroshima, Japan
[5] Kure Med Ctr, Dept Resp Internal Med, Hiroshima, Japan
[6] Hiroshima Univ Hosp, Hiroshima, Japan
[7] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Internal Med, Hiroshima, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21156
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1
    Masuda, Takeshi
    Fujitaka, Kazunori
    Suzuki, Tomoko
    Hamai, Kosuke
    Matsumoto, Naoko
    Matsumura, Mirai
    Isoyama, Shoko
    Ueno, Sayaka
    Mito, Mineyo
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Kawano, Reo
    Masuda, Ken
    Nishino, Ryohei
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Hattori, Noboru
    THORACIC CANCER, 2022, 13 (11) : 1611 - 1618
  • [2] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [3] Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥ 50%) non-small cell lung cancer.
    De Castro Barrichello, Adriana Paula
    Alessi, Joao Victor Machado
    Ricciuti, Biagio
    Pecci, Federica
    Vaz, Victor R.
    Lamberti, Giuseppe
    Turner, Madison M.
    Pfaff, Kathleen L.
    Rodig, Scott J.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
    Alessi, Joao, V
    Ricciuti, Biagio
    Jimenez-Aguilar, Elizabeth
    Hong, Fangxin
    Wei, Zihan
    Nishino, Mizuki
    Plodkowski, Andrew J.
    Sawan, Peter
    Luo, Jia
    Rizyi, Hira
    Carter, Brett W.
    Heymach, John, V
    Altan, Mehmet
    Hellmann, Matthew
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [5] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [6] First-line immunotherapy in PD-L1-high non-small cell lung cancer: indirect treatment comparison of pembrolizumab and atezolizumab
    Griesinger, F.
    Sibbe, M. S.
    Hieke-Schulz, S.
    Buhck, H.
    Reinmuth, N.
    Rittmeyer, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 227 - 228
  • [7] Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
    Aguilar, Elizabeth Jimenez
    Ricciuti, Biagio
    Gainor, Justin F.
    Nishino, Mizuki
    Adeni, Anika E.
    Subegdjo, Safiya
    Khosrowjerdi, Sara
    Peterson, Rachel
    Digumarthy, Subba
    Liu, Corinne
    Sauter, Jennifer L.
    Rizvi, Hira
    Arbour, Kathryn Cecilia
    Carter, Brett W.
    Heymach, John
    Altan, Mehmet
    Hellmann, Matthew David
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
  • [9] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Aguilar, E. J.
    Ricciuti, B.
    Gainor, J. F.
    Kehl, K. L.
    Kravets, S.
    Dahlberg, S.
    Nishino, M.
    Sholl, L. M.
    Adeni, A.
    Subegdjo, S.
    Khosrowjerdi, S.
    Peterson, R. M.
    Digumarthy, S.
    Liu, C.
    Sauter, J.
    Rizvi, H.
    Arbour, K. C.
    Carter, B. W.
    Heymach, J. V.
    Altan, M.
    Hellmann, M. D.
    Awad, M. M.
    ANNALS OF ONCOLOGY, 2019, 30 (10) : 1653 - 1659
12345